OBJECTIVE: The Fli-1 transcription factor is implicated in the pathogenesis of systemic lupus erythematosus (SLE), both in humans and in animal models. Dysregulation of interleukin-6 (IL-6) is also associated with SLE. The purpose of this study was to investigate whether Fli-1 directly regulates the expression of IL-6. METHODS: Sera were collected from wild-type and Fli-1-heterozygous (Fli-1(+/-) ) MRL/lpr mice, and the concentration of IL-6 was measured by enzyme-linked immunosorbent assay (ELISA). Expression of IL-6 in the kidney was measured by real-time polymerase chain reaction analysis. T cells were isolated from wild-type and Fli-1(+/-) MRL/lpr mice and stimulated with CD3/CD28 beads, and the concentration of IL-6 in the supernatants was measured by ELISA. MS1 endothelial cells were transfected with Fli-1 and control small interfering RNA, and the production of IL-6 was compared after lipopolysaccharide stimulation. A chromatin immunoprecipitation (ChIP) assay was performed to determine whether Fli-1 binds to the IL-6 promoter region. Transient transfections with the NIH3T3 cell line were performed to examine whether Fli-1 regulates the expression of IL-6. RESULTS: Fli-1(+/-) MRL/lpr mice had significantly decreased IL-6 levels in sera and reduced expression of IL-6 in kidneys as compared to their wild-type littermates. T cells isolated from Fli-1(+/-) MRL/lpr mice produced less IL-6 than did those from wild-type mice. Inhibiting the expression of Fli-1 in endothelial cells resulted in reduced production of IL-6. The ChIP assay revealed direct binding of Fli-1 to 3 regions within the IL-6 promoter. Fli-1 activated transcription from the IL-6 promoter in a dose-dependent manner. CONCLUSION: The direct regulation of IL-6 expression by Fli-1 represents one possible mechanism for the protective effect of decreased Fli-1 expression in lupus.
OBJECTIVE: The Fli-1 transcription factor is implicated in the pathogenesis of systemic lupus erythematosus (SLE), both in humans and in animal models. Dysregulation of interleukin-6 (IL-6) is also associated with SLE. The purpose of this study was to investigate whether Fli-1 directly regulates the expression of IL-6. METHODS: Sera were collected from wild-type and Fli-1-heterozygous (Fli-1(+/-) ) MRL/lprmice, and the concentration of IL-6 was measured by enzyme-linked immunosorbent assay (ELISA). Expression of IL-6 in the kidney was measured by real-time polymerase chain reaction analysis. T cells were isolated from wild-type and Fli-1(+/-) MRL/lprmice and stimulated with CD3/CD28 beads, and the concentration of IL-6 in the supernatants was measured by ELISA. MS1 endothelial cells were transfected with Fli-1 and control small interfering RNA, and the production of IL-6 was compared after lipopolysaccharide stimulation. A chromatin immunoprecipitation (ChIP) assay was performed to determine whether Fli-1 binds to the IL-6 promoter region. Transient transfections with the NIH3T3 cell line were performed to examine whether Fli-1 regulates the expression of IL-6. RESULTS:Fli-1(+/-) MRL/lprmice had significantly decreased IL-6 levels in sera and reduced expression of IL-6 in kidneys as compared to their wild-type littermates. T cells isolated from Fli-1(+/-) MRL/lprmice produced less IL-6 than did those from wild-type mice. Inhibiting the expression of Fli-1 in endothelial cells resulted in reduced production of IL-6. The ChIP assay revealed direct binding of Fli-1 to 3 regions within the IL-6 promoter. Fli-1 activated transcription from the IL-6 promoter in a dose-dependent manner. CONCLUSION: The direct regulation of IL-6 expression by Fli-1 represents one possible mechanism for the protective effect of decreased Fli-1 expression in lupus.
Authors: Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky Journal: Arthritis Rheum Date: 2010-02
Authors: Eiji Suzuki; Eva Karam; Sarah Williams; Dennis K Watson; Gary Gilkeson; Xian K Zhang Journal: Clin Immunol Date: 2012-09-28 Impact factor: 3.969
Authors: Xian K Zhang; Omar Moussa; Amanda LaRue; Sarah Bradshaw; Ivan Molano; Demetri D Spyropoulos; Gary S Gilkeson; Dennis K Watson Journal: J Immunol Date: 2008-08-01 Impact factor: 5.422
Authors: Mara L Lennard Richard; Danielle Brandon; Ning Lou; Shuzo Sato; Tomika Caldwell; Tamara K Nowling; Gary Gilkeson; Xian K Zhang Journal: Eur J Immunol Date: 2016-08-16 Impact factor: 5.532
Authors: Pengfei Li; Andrew J Goodwin; James A Cook; Perry V Halushka; Xian K Zhang; Hongkuan Fan Journal: Mol Immunol Date: 2019-02-08 Impact factor: 4.407
Authors: Pengfei Li; Yue Zhou; Andrew J Goodwin; James A Cook; Perry V Halushka; Xian K Zhang; Carole L Wilson; Lynn M Schnapp; Basilia Zingarelli; Hongkuan Fan Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: Pengfei Li; Yan Wu; Eric D Hamlett; Andrew J Goodwin; Perry V Halushka; Steven L Carroll; Meng Liu; Hongkuan Fan Journal: Mol Ther Date: 2022-01-14 Impact factor: 12.910
Authors: Kamala P Sundararaj; Thirumagal Thiyagarajan; Ivan Molano; Fahmin Basher; Thomas W Powers; Richard R Drake; Tamara K Nowling Journal: J Immunol Date: 2015-11-04 Impact factor: 5.422